文献速递胸部肿瘤放疗放疗物理与技术

局部晚期肺癌放疗中的心脏剂量:全州联盟结果

Cardiac Dose in Locally Advanced Lung Cancer: Results From a Statewide Consortium.
PubMed 文献 · Pract Radiat Oncol · 2019-08-02

基于密歇根放射肿瘤质量联盟2012–2017年746例III期非小细胞肺癌放疗患者,分析心脏剂量及实践模式。中位平均心脏剂量12 Gy,1/4患者平均心脏剂量超过20 Gy;IMRT使用率从33%升至86%,与V30 Gy和V50 Gy百分比降低相关,但未降低平均剂量。无统一心脏剂量约束。

要点

  • 中位平均心脏剂量12 Gy,1/4患者超过20 Gy。
  • IMRT使用率从33%升至86%,与V30 Gy和V50 Gy降低相关。
  • 无统一心脏剂量约束,需标准化约束并优化治疗技术。

核心结论

  • 多数病例满足历史心脏约束,但1/4患者平均心脏剂量超过20 Gy。
  • IMRT与心脏V30 Gy和V50 Gy百分比降低相关,但不降低平均剂量。
  • 需标准化心脏剂量约束并开发不牺牲其他计划目标的治疗方法。

研究设计与样本

  • 2012–2017年密歇根放射肿瘤质量联盟(MROQC)内746例III期非小细胞肺癌放疗患者的队列分析。
  • 分析心脏剂量特征、实践模式,采用多变量回归和逆概率加权分析关联。

主要发现

  • 中位平均心脏剂量12 Gy(IQR 5–19 Gy),5%患者V30 Gy超过50%,3%患者V40 Gy超过35%。
  • IMRT使用率从2012年33%增至2017年86%(P < .001),与更大PTV、更高分期和既存心脏病相关。
  • 多变量回归:IMRT与V30 Gy绝对降低3.0%(95%CI 0.5%–5.4%)和V50 Gy绝对降低3.6%(95%CI 2.4%–4.8%)相关,与平均剂量无关。

关键数值与推荐

  • 中位处方剂量60 Gy(IQR 60–66 Gy)。
  • 中位平均心脏剂量12 Gy(IQR 5–19 Gy)。
  • V30 Gy超过50%见于5%患者,V40 Gy超过35%见于3%患者。
  • IMRT与V30 Gy绝对降低3.0%(95%CI 0.5%–5.4%)和V50 Gy绝对降低3.6%(95%CI 2.4%–4.8%)相关。
  • IMRT与心脏V40–V60 Gy百分比相对降低29%–48%相关。

临床怎么用

  • 临床中应关注平均心脏剂量,即使满足历史约束,仍有1/4患者平均剂量超过20 Gy。
  • 考虑使用IMRT降低心脏V30–V60 Gy受量,且不增加肺或食管剂量或损害PTV覆盖。
  • 需建立统一心脏剂量约束以标准化实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The heart has been identified as a potential significant organ at risk in patients with locally advanced non-small cell lung cancer treated with radiation. Practice patterns and radiation dose delivered to the heart in routine practice in academic and community settings are unknown. METHODS AND MATERIALS: Between 2012 and 2017, 746 patients with stage III non-small cell lung cancer were treated with radiation within the statewide Michigan Radiation Oncology Quality Consortium (MROQC). Cardiac radiation dose was characterized, including mean and those exceeding historical or recently proposed Radiation Therapy Oncology Group and NRG Oncology constraints. Sites were surveyed to determine dose constraints used in practice. Patient-, anatomic-, and treatment-related associations with cardiac dose were analyzed using multivariable regression analysis and inverse probability weighting. RESULTS: Thirty-eight percent of patients had a left-sided primary, and 80% had N2 or N3 disease. Median prescription was 60 Gy (interquartile range, 60-66 Gy). Twenty-two percent of patients were prescribed 60 Gy in 2012, which increased to 62% by 2017 (P < .001). Median mean heart dose was 12 Gy (interquartile range, 5-19 Gy). The volume receiving 30 Gy (V30 Gy) exceeded 50% in 5% of patients, and V40 Gy was >35% in 3% of cases. No heart dose constraint was uniformly applied. Intensity modulated radiation therapy (IMRT) usage increased from 33% in 2012 to 86% in 2017 (P < .001) and was significantly associated with more complex cases (larger planning target volume, higher stage, and preexisting cardiac disease). In multivariable regression analysis, IMRT was associated with a lower percent of the heart receiving V30 Gy (absolute reduction = 3.0%; 95% confidence interval, 0.5%-5.4%) and V50 Gy (absolute reduction = 3.6%; 95% confidence interval, 2.4%-4.8%) but not mean dose. In inverse probability weighting analysis, IMRT was associated with 29% to 48% relative reduction in percent of the heart receiving V40-V60 Gy without increasing lung or esophageal dose or compromising planning target volume coverage. CONCLUSIONS: Within MROQC, historical cardiac constraints were met in most cases, yet 1 in 4 patients received a mean heart dose exceeding 20 Gy. Future work is required to standardize heart dose constraints and to develop treatment approaches that allow for constraints to be met without compromising other planning goals.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dess RT, Sun Y, Muenz DG, et al. Cardiac Dose in Locally Advanced Lung Cancer: Results From a Statewide Consortium. Pract Radiat Oncol. 2019. PMID: 31382026. doi:10.1016/j.prro.2019.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。